SCHEMBL7683722

SCHEMBL7683722

COc1ccc(S(=O)(=O)N2CCN(C(=O)CCCc3ccccc3)C[C@H]2C(=O)O)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 2/20 0.50
POLB P06746 1/20 0.49
MMP1 P03956 5/20 0.48
MMP3 P08254 5/20 0.48
MMP7 P09237 5/20 0.48
MMP9 P14780 5/20 0.48
MMP13 P45452 4/20 0.48
GAA P10253 2/20 0.47
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PDE4A P27815 2/20 0.46
PDE4B Q07343 2/20 0.46
PDE4C Q08493 2/20 0.46
PDE4D Q08499 2/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPT P10636 1/20 0.45
USP2 O75604 1/20 0.44
TSHR P16473 1/20 0.44
PLAAT3 P53816 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7683726 1.00 FKBP1A (0.50) FKBP1APOLBMMP1MMP3MMP7
SCHEMBL7690366 0.88 MMP1 (0.62) MMP1MMP3MMP7MMP9MMP13
SCHEMBL7684949 0.86 MMP1 (0.50) FKBP1APOLBMMP1MMP3MMP7
SCHEMBL7687390 0.83 MMP1 (0.64) FKBP1APOLBMMP1MMP3MMP7
SCHEMBL7683254 0.78 MMP1 (0.64) POLBMMP1MMP3MMP7MMP9
SCHEMBL7685735 0.77 MMP1 (0.58) POLBMMP1MMP3MMP7MMP9
SCHEMBL7685731 0.77 MMP1 (0.58) POLBMMP1MMP3MMP7MMP9
SCHEMBL7685520 0.77 MMP1 (0.60) MMP1MMP3MMP7MMP9MMP13
SCHEMBL7686447 0.77 MMP1 (0.60) MMP1MMP3MMP7MMP9MMP13
SCHEMBL2706470 0.74 HCRTR1 (0.67) FKBP1AALDH1A1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020128269-A1 Substituted heterocyclic compounds for treating multidrug resistance PROCTER & GAMBLE COMPANY, THE 2002-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128269-A1 Substituted heterocyclic compounds for treating multidrug resistance ABCC1, ABCB1, ABCG2 FKBP1A 2904/4885POLB 235/4885MMP1 3802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.